Ionis Pharmaceuticals, Inc. stock sank after earnings as 2026 sales guidance was cut and launch woes grew. Click for this IONS update.
Ionis stock sank after Tryngolza sales guidance was slashed despite a Q3 earnings beat.
The full data from the closely watched clinical trial showed that the drug had no cardiovascular benefit even though it reduced Lp(a) levels.
Shares of Ionis Pharmaceuticals sink after it slashes full-year revenue guidance for one of its flagship drugs.
Premarket trading suggests Ionis Pharmaceuticals will open at its lowest point since May 2025.
This is the newest page. Registered accounts read further back.